Discontinued — last reported Q4 '25
Aflac Interest Paid decreased by 20.3% to $51.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 27.5%, from $40.00M to $51.00M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows relatively stable performance with a -1.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $74.00M | $37.00M | $67.00M | $37.00M | $67.00M | $49.00M | $58.00M | $37.00M | $57.00M | $38.00M | $53.00M | $34.00M | $53.00M | $40.00M | $53.00M | $40.00M | $52.00M | $41.00M | $64.00M | $51.00M |
| QoQ Change | — | -50.0% | +81.1% | -44.8% | +81.1% | -26.9% | +18.4% | -36.2% | +54.1% | -33.3% | +39.5% | -35.8% | +55.9% | -24.5% | +32.5% | -24.5% | +30.0% | -21.2% | +56.1% | -20.3% |
| YoY Change | — | — | — | — | -9.5% | +32.4% | -13.4% | +0.0% | -14.9% | -22.4% | -8.6% | -8.1% | -7.0% | +5.3% | +0.0% | +17.6% | -1.9% | +2.5% | +20.8% | +27.5% |